Accuracy of MRI for treatment response assessment after taxane- and anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer

European Journal of Surgical Oncology

Volumn 40, Issue 10, 2014, Pages 1216-1221

  Charehbili, A ^a   Wasser, M N ^a   Smit, V T H B M ^a   Putter, H ^a   Van Leeuwen Stok, A E ^b   Meershoek Klein Kranenbarg, W M ^a   Liefers, G J ^a   Van De Velde, C J H ^a   Nortier, J W R ^a   Kroep, J R ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Dutch Breast Cancer Research Group (BOOG)   (Netherlands)

Author keywords

Breast neoplasms; Magnetic resonance imaging; Neoadjuvant therapy; Surgery

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE; TAXOID;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SIZE; COHORT ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AGED; AREA UNDER THE CURVE; BREAST; BREAST NEOPLASMS; CARCINOMA; CONTROLLED STUDY; METABOLISM; MIDDLE AGED; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BREAST; BREAST NEOPLASMS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DIPHOSPHONATES; DOXORUBICIN; FEMALE; HUMANS; IMIDAZOLES; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOADJUVANT THERAPY; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; ROC CURVE; TAXOIDS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84925224919     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2014.07.036     Document Type: Article

References (23)

1. P. Cortazar, L. Zhang, and M. Untch et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis Lancet 384 9938 2014 Jul 12 164 172
2. M.L. Marinovich, P. Macaskill, and L. Irwig et al. Meta-analysis of agreement between MRI and pathologic breast tumour size after neoadjuvant chemotherapy Br J Cancer 109 6 2013 1528 1536
3. P.J. Drew, S. Chatterjee, and L.W. Turnbull et al. Dynamic contrast enhanced magnetic resonance imaging of the breast is superior to triple assessment for the pre-operative detection of multifocal breast cancer Ann Surg Oncol 6 6 1999 599 603
4. Y. Yuan, X.S. Chen, S.Y. Liu, and K.W. Shen Accuracy of MRI in prediction of pathologic complete remission in breast cancer after preoperative therapy: a meta-analysis AJR Am J Roentgenol 195 1 2010 260 268
5. M.B. Lobbes, R. Prevos, and M. Smidt et al. The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review Insights Imaging 4 2 2013 163 175
6. L.M. Wu, J.N. Hu, H.Y. Gu, J. Hua, J. Chen, and J.R. Xu Can diffusion-weighted MR imaging and contrast-enhanced MR imaging precisely evaluate and predict pathological response to neoadjuvant chemotherapy in patients with breast cancer? Breast Cancer Res Treat 135 1 2012 17 28
7. S.J. De Los, W. Bernreuter, and K. Keene et al. Accuracy of breast magnetic resonance imaging in predicting pathologic response in patients treated with neoadjuvant chemotherapy Clin Breast Cancer 11 5 2011 312 319
8. Y. Hayashi, H. Takei, and S. Nozu et al. Analysis of complete response by MRI following neoadjuvant chemotherapy predicts pathological tumor responses differently for molecular subtypes of breast cancer Oncol Lett 5 1 2013 83 89
9. H.G. Moon, W. Han, and S.K. Ahn et al. Breast cancer molecular phenotype and the use of HER2-targeted agents influence the accuracy of breast MRI after neoadjuvant chemotherapy Ann Surg 257 1 2013 133 137
10. C.E. Loo, M.E. Straver, and S. Rodenhuis et al. Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype J Clin Oncol 29 6 2011 660 666
11. E.S. Ko, B.K. Han, and R.B. Kim et al. Analysis of factors that influence the accuracy of magnetic resonance imaging for predicting response after neoadjuvant chemotherapy in locally advanced breast cancer Ann Surg Oncol 20 8 2013 2562 2568
12. A. Kuzucan, J.H. Chen, and S. Bahri et al. Diagnostic performance of magnetic resonance imaging for assessing tumor response in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy is associated with molecular biomarker profile Clin Breast Cancer 12 2 2012 110 118
13. J.H. Chen, B. Feig, and G. Agrawal et al. MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy Cancer 112 1 2008 17 26
14. J.H. Chen, S. Bahri, and R.S. Mehta et al. Breast cancer: evaluation of response to neoadjuvant chemotherapy with 3.0-T MR imaging Radiology 261 3 2011 735 743
15. J.F. De Los Santos, A. Cantor, and K.D. Amos et al. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium Trial 017 Cancer 119 10 2013 1776 1783
16. R.A. Mukhtar, C. Yau, M. Rosen, V.J. Tandon, N. Hylton, and L.J. Esserman Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 trial (CALGB 150007/150012; ACRIN 6657) Ann Surg Oncol 20 12 2013 3823 3830
17. H.G. Moon, W. Han, and J.W. Lee et al. Age and HER2 expression status affect MRI accuracy in predicting residual tumor extent after neo-adjuvant systemic treatment Ann Oncol 20 4 2009 636 641
18. F. Denis, A.V. Desbiez-Bourcier, C. Chapiron, F. Arbion, G. Body, and L. Brunereau Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer Eur J Surg Oncol 30 10 2004 1069 1076
19. A. Charehbili, S. van de Ven, and V.T. Smit et al. Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2 negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01) Ann Oncol 25 5 2014 May 998 1004
20. E.A. Eisenhauer, P. Therasse, and J. Bogaerts et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2 2009 228 247
21. K.L. Blackwell, M.W. Dewhirst, and V. Liotcheva et al. HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors Clin Cancer Res 10 12 Pt 1 2004 4083 4088
22. A. Vacca, D. Ribatti, and M. Iurlaro et al. Docetaxel versus paclitaxel for antiangiogenesis J Hematother Stem Cell Res 11 1 2002 103 118
23. N.M. Hylton, J.D. Blume, and W.K. Bernreuter et al. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy-results from ACRIN 6657/I-SPY trial Radiology 263 3 2012 663 672